Financial Wire

Erdene Resource's Bayan Khundii Mine Records 94% of Target Production Throughput in Q1

-- Erdene Resource Development (ERD.TO) said Monday that the Bayan Khundii gold mine in Mongolia achieved 94% of the target production throughput during the first quarter.

The mine achieved commercial production in the first quarter, processing 151,000 tonnes of ore for an average of 1,675 tonnes per day.

Bayan Khundii also recorded an average throughput of nearly 90% of nameplate capacity while gold recovery averaged over 96%, exceeding projections in the most recent feasibility study.

To date, the mine has produced 15,961 ounces of gold, Erdene said.

Erdene Mongol, Erdene Resource's joint venture with Mongolian Mining, generated gross revenues of US$42 million during the quarter after it recorded sales of 8,527 ounces of gold and 3,135 ounces of silver. Average prices stood at $4,872/oz of gold and $80/oz of silver.

Related Articles

Australia

BofA Adjusts Price Target on Pool to $226 From $229

Pool (POOL) has an average rating of overweight and mean price target of $262.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $228.70, Change: $+1.08, Percent Change: +0.47%

$POOL
Australia

BofA Adjusts Price Target on SiteOne Landscape Supply to $167 From $182

SiteOne Landscape Supply (SITE) has an average rating of overweight and mean price target of $169.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $142.26, Change: $-2.10, Percent Change: -1.45%

$SITE
Australia

Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility

Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%

$GILD$RCUS